Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.39 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | LIPE | Q05469 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MTHFD2 | P13995 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697869 | 0.95 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1KMT2APKM | |
| SCHEMBL13547376 | 0.93 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1KMT2APKM | |
| SCHEMBL362028 | 0.91 | PKM (0.40) | TRIM24TRIM33ALDH1A1KMT2APKM | |
| SCHEMBL217162 | 0.82 | HSP90AA1 (0.34) | TRIM24TRIM33ALDH1A1KMT2ALMNA | |
| SCHEMBL641829 | 0.80 | CYP1A2 (0.43) | TRIM24TRIM33ALDH1A1LIPE | |
| SCHEMBL60542 | 0.76 | — | — | |
| SCHEMBL13327604 | 0.76 | ALDH1A1 (0.59) | ALDH1A1KMT2APOLBLMNALIPE | |
| SCHEMBL2573205 | 0.76 | TRIM24 (0.38) | TRIM24TRIM33ALDH1A1KMT2AHPGD | |
| SCHEMBL12517389 | 0.76 | HSP90AA1 (0.38) | ALDH1A1HPGDHSP90AA1 | |
| SCHEMBL655840 | 0.75 | BLM (0.42) | ALDH1A1KMT2APKMLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068951-A1 | COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3083583-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF | SAGIMET BIOSCIENCES INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MERCK SHARP & DOHME CORP. (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2008077057-A2 | CYTOSKELETAL ACTIVE RHO KINASE INHIBITOR COMPOUNDS, COMPOSITION AND USE | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1863483-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | Janssen Pharmaceutica, N.V. (BE) | 2007-12-12 | — | — | EP | disclosed |
| EP-1851219-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | Miikana Therapeutics, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| CN-1976911-A | Arylphenylamino-, arylphenylamide-and arylphenylether-thioether derivatives | ICOS CORP (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006105289-A1 | BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006088949-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | EISAI CO., LTD. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281913-A1 | Metallo-Beta-Lactamase Inhibitors and Methods of Use Thereof | MLX, MMP12, SLC11A2 | TRIM24 2257/4885TRIM33 3409/4885ALDH1A1 282/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | TRIM24 2656/4885TRIM33 3948/4885ALDH1A1 768/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | TRIM24 4439/4885TRIM33 3811/4885ALDH1A1 58/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | TRIM24 2545/4885TRIM33 3747/4885ALDH1A1 724/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | TRIM24 2545/4885TRIM33 3747/4885ALDH1A1 724/4885 |
| US-11207312-B2 | Metallo-beta-lactamase inhibitors and methods of use thereof | MLX, MMP12, SLC11A2 | TRIM24 2257/4885TRIM33 3409/4885ALDH1A1 282/4885 |
| US-20060004013-A1 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; 3E)-1-[(1S)-1-(4-fluorophenyl)ethyl]-3-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene]piperidin-2-one; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42; low hygroscopicity; good solubility | PSEN1, APP, BACE1 | TRIM24 1456/4885TRIM33 496/4885ALDH1A1 1375/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | TRIM24 2545/4885TRIM33 3747/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.